Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas

In this podcast episode, listen to Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, as they answer questions on managing NF1 and using MEK inhibitors for NF1-associated plexiform neurofibromas.
person default
Scott Plotkin, MD, PhD
person default
Brian D. Weiss, MD
Released: July 12, 2021

In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including:  

  • Whole exome sequencing for diagnosis
  • When to treat asymptomatic tumors
  • Genetic testing of family members
  • Choosing a MEK inhibitor
  • Supportive care for acneiform rash
  • Other RAS pathway inhibitors

Presenters:

Scott R. Plotkin, MD, PhD
Executive Director
Pappas Center for Neuro-Oncology
Professor of Neurology
Harvard Medical School
Boston, Massachusetts

Brian D. Weiss, MD
Clinical Professor of Pediatrics
Cancer and Blood Diseases Institute Division of Oncology  
Medical Director
Solid Tumor Program
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Related Content

Expert commentary from Dr. Scott R. Plotkin on using MEK inhibitors for neurofibromatosis 1 (NF1), from Clinical Care Options (CCO)

person default Scott Plotkin, MD, PhD Released: August 2, 2021

On-demand webcast on plexiform neurofibromas in neurofibromatosis type 1 (NF1) featuring 2 faculty experts presented by Clinical Care Options (CCO)

person default Scott Plotkin, MD, PhD person default Brian D. Weiss, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) Released: July 13, 2021 Expired: July 12, 2022

Downloadable PDF with highlights from a CCO podcast on managing neurofibromatosis type 1 and MEK inhibitors plexiform neurofibromas.

person default Scott Plotkin, MD, PhD person default Brian D. Weiss, MD Released: July 12, 2021

Downloadable slideset covering MEK inhibitors for plexiform neurofibromas in patients with NF1, from Clinical Care Options (CCO)

person default Brian D. Weiss, MD Released: June 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue